- Home
- ODYS vs PLRX Comparison
ODYS vs PLRX Comparison
Compare ODYS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- PLRX
- Stock Information
- Founded
- ODYS N/A
- PLRX 2015
- Country
- ODYS Israel
- PLRX United States
- Employees
- ODYS N/A
- PLRX N/A
- Industry
- ODYS
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ODYS
- PLRX Health Care
- Exchange
- ODYS NYSE
- PLRX Nasdaq
- Market Cap
- ODYS 86.1M
- PLRX 84.7M
- IPO Year
- ODYS N/A
- PLRX 2020
- Fundamental
- Price
- ODYS $5.07
- PLRX $1.37
- Analyst Decision
- ODYS Strong Buy
- PLRX Hold
- Analyst Count
- ODYS 1
- PLRX 10
- Target Price
- ODYS $10.00
- PLRX $9.79
- AVG Volume (30 Days)
- ODYS 8.9K
- PLRX 1.1M
- Earning Date
- ODYS 08-11-2025
- PLRX 08-06-2025
- Dividend Yield
- ODYS N/A
- PLRX N/A
- EPS Growth
- ODYS N/A
- PLRX N/A
- EPS
- ODYS N/A
- PLRX N/A
- Revenue
- ODYS $5,842,000.00
- PLRX N/A
- Revenue This Year
- ODYS N/A
- PLRX N/A
- Revenue Next Year
- ODYS N/A
- PLRX N/A
- P/E Ratio
- ODYS N/A
- PLRX N/A
- Revenue Growth
- ODYS 100.27
- PLRX N/A
- 52 Week Low
- ODYS $4.83
- PLRX $1.10
- 52 Week High
- ODYS $10.80
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- PLRX 42.47
- Support Level
- ODYS N/A
- PLRX $1.56
- Resistance Level
- ODYS N/A
- PLRX $1.70
- Average True Range (ATR)
- ODYS 0.00
- PLRX 0.11
- MACD
- ODYS 0.00
- PLRX -0.00
- Stochastic Oscillator
- ODYS 0.00
- PLRX 27.59
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.